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The hypervariable region 1 (HVR1) of the putative envelope 2 protein of the hepatitis C virus (HCV) is the most variable part of
the whole HCV polyprotein. Anti-HVR1 antibodies have been shown to protect against HCV infection, indicating that this region
contains an important neutralization determinant. Recently we and others have demonstrated that HVR1 is also a T cell
determinant able to activate helper T cell responses during HCV infection. In order to investigate the role of the immune response
against HVR1 during HCV infection we have evaluated the humoral and lymphoproliferative responses to a panel of HVR1 peptides
in HCV-infected patients with different outcomes of the disease following interferon-a (IFN-a) treatment. We observed that the
frequency of anti-HVR1 T cell responses was significantly higher in patients who recovered after IFN-a therapy than in those who
did not, while no differences in the anti-HVR1 antibody reactivities were detected. In addition, by generating HVR1-specific T cell
lines and clones we identified human leukocyte-associated antigens DR4 restricted T cell epitopes in the carboxy-terminus of
HVR1 and we demonstrated that broadly cross-reactive HVR1 T cells are elicited by HVR1. © 2000 Academic Press
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Hepatitis C virus (HCV) is one of the major etiologic
agents of chronic hepatitis around the world (Choo et al.,
1989). Chronic infections develop in more than 50% of
patients, eventually leading to cirrhosis and hepatocellular
carcinoma (Alter, 1995). Treatment with interferon-a (IFN-a)
s the only available therapy, but long-term benefit is ob-
ained in about 20% of treated cases (Davis et al., 1989). For
his reason the development of an anti-HCV vaccine repre-
ents an urgent need although a major obstacle to this goal
s the high variability of the virus (Martell et al., 1992; Kuro-
aki et al., 1994; Enomoto and Sato, 1995). Within the HCV
olyprotein in the amino-terminus of E2 a hypervariable
egion (HVR1) consisting of 27 amino acids (aa) has been
dentified (Weiner et al., 1991). This region is the most
ariable part of the HCV genome and appears to induce
eutralizing antibodies (Zibert et al., 1995; Shimizu et al.,
996; Farci et al., 1994, 1996). Recently some investigators,
ncluding our group, have isolated HVR1-specific helper T
ells from peripheral blood mononuclear cells (PBMC) of
CV-infected individuals, demonstrating that HVR1 con-
ains T cell epitopes restricted by human leukocyte-asso-
iated antigens (HLA-DR) molecules (Frasca et al., 1999;
hirai et al., 1999). Such helper T cells were also detected
n mice immunized with HVR1 variants and in both species
t could be observed that the anti-HVR1 responses showed
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Cellular and Developmental Biology, Univer-
ity of Rome “La Sapienza,” Via degli Apuli 1, 00185 Rome, Italy. Fax:s9-06-49917594. E-mail: pdelport@axcasp.caspur.it.
313certain degree of cross-reactivity. Interestingly, the pres-
nce of antibodies directed to HVR1 was correlated with
elper T cell responsiveness to this region in mice and
umans, leading to the hypothesis that the cellular re-
ponse to HVR1 can contribute to the outcome of the
nfection, helping B cells to produce neutralizing antibodies
Shirai et al., 1999). In order to obtain insight into the role of
he anti-HVR1 immune responses during HCV infection, in
he present study we evaluated the lymphoproliferative re-
ponses and sera reactivity to HVR1 in 44 IFN-a treated
patients with different outcomes of the disease. In addition
we analyzed the extent of cross-reactivity of the HVR1-
specific T cell response by performing a detailed analysis
of the specificity of anti-HVR1 T cell lines and clones. Our
results demonstrate that (1) HVR1-specific T cell responses
are significantly more frequent in patients who succeeded
in normalizing the biochemical parameters of disease ac-
tivity than in those who maintained elevated transaminase
values following IFN-a treatment; (2) antibodies to HVR1 are
frequently detected in sera of patients and do not correlate
with the response to IFN-a; and (3) broadly cross-reactive
CD41 T cells are present in the HVR1 T cell repertoire.
RESULTS
roliferative responses to HVR1 are frequently
etected in PBMC from HCV-infected chronic patients
nd correlate with long-term response
o IFN-a treatment
To investigate the role of anti-HVR1 T cell response
uring HCV infection we analyzed the proliferative re-
ponses of PBMC to synthetic peptides reproducing
0042-6822/00 $35.00
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314 DEL PORTO ET AL.HVR1 from natural isolates. Due to the wide inter- and
intraindividual HVR1 heterogeneity and in the absence of
any knowledge of the specific variant of the infecting
quasispecies that may have induced a response in the
patients analyzed, we used a panel of peptides repro-
ducing HVR1 from natural isolates selected from those
available in the databases to represent highly divergent
naturally occurring variants. This was done by a multidi-
mensional cluster analysis performed on 234 aligned
natural HVR1 sequences (Casari et al., 1995). Forty-three
sequences nearly homogeneously distributed over the
HVR1 “sequence space” were identified (Puntoriero et al.,
1998) and of these, the first 13 sequences were chosen
and synthesized as multiple antigenic peptides (MAPs;
Pessi et al., 1990). Among these, 8 MAPs were used in
proliferation assays of PBMC from IFN-a-treated HCV
patients described in Table 1. As control of PBMC prolif-
eration 5 U/ml of human recombinant IL-2 (rIL-2) was
added to each culture. We found that PBMC from 16
patients (30%) showed a significant response to at least
one of the HVR1 variants and that in about half of these
patients reactivity was directed to multiple HVR1 peptide
variants (Table 2). Moreover, all 8 variants were immu-
nogenic even if they showed different induction frequen-
cies of T cell proliferation: from 1.8% for variant 291 to
20% for variant 269 (Table 2). Proliferation was specific
since none of the 15 HCV sero-negative controls re-
sponded to any HVR1 peptide (Table 3).
We next evaluated the frequency of the proliferative
responses in the patients studied who were classified
according to the outcome of the disease following IFN-a
treatment. Twenty-four patients showed a sustained nor-
malization of liver enzymes even after cessation of the
therapy (long-term responders: LTR). Five showed nor-
malized aminotransferase (ALT) activity having finished
the IFN-a treatment within 6 months (responders: R), 4
showed normalized ALT activity only during IFN-a treat-
ment (responders with relapse: RR), and 20 did not re-
spond to IFN-a (nonresponders: NR). As shown in Table
, HVR1-specific T cell proliferation was detected in 11 of
T
Clinical and Virological Chara
Patient typea n
Age
(years)
Sex
(F/M)
Patho
(C/CAH/CPH
LTR 24 50 6 14 10/14 0/13
NR 20 53 6 11 12/8 1/14
R 5 50 6 20 0/5 0/4/0
RR 4 34 6 7 3/1 0/2/2
C 15 34 6 8 8/7
a Patients treated with IFN-a included LTR, long-term responders; NR
o healthy controls.
b Histological status of liver specimens. C, cirrhosis, CAH, chronic a
c Genotype was determined according to Simmonds et al. (1993).4 LTR (45%), 3 of 20 NR (15%), 2 of 5 R (40%), and in none tf the RR patients. The difference between LTR and NR
as statistically significant (P , 0.03), indicating an
association between the activation of HVR1-specific T
cells and a positive response to IFN-a. A similar trend
as also observed in the anti-HVR1 responses in RR and
patients, although in these cases the limited number of
atients did not allow a statistically significant correla-
ion to be established. On the contrary, statistical analy-
is of rIL-2-induced lymphoproliferation (expressed as
ean values of sample counts per minute with substrac-
ion of the medium control wells) of LTR (24,710 6 14,466)
nd NR (26,176 6 13,881) did not reveal any significant
ifference.
nti-HVR1 antibodies detected in sera from HCV-
nfected chronic patients do not correlate with
ong-term response to IFN-a treatment
The observed correlation between the T cell response
to HVR1 and the outcome of the IFN-a treatment led us
o investigate whether any difference in the prevalence
f anti-HVR1 antibodies could be detected in the LTR and
R patients. To this aim we assessed the antibody re-
ctivity of sera from the 24 LTR and 20 NR patients to the
ame panel of eight HVR1 peptides. As reported in Fig. 1
era from 34 patients (77%) recognized HVR1 sequences
nd the majority of them were simultaneously reactive to
ultiple variants. With the exception of variant 275,
hich was not recognized by any of the sera, and variant
77, which was scored positive by only four sera, all the
ariant peptides were recognized by antibodies present
n a significant fraction of the tested population, ranging
rom 23 to 48%. In this case, LTR and NR patients showed
imilar frequencies of reactivity (75 and 80%, respec-
ively; Fig. 1), suggesting that no correlation between
ntibody response and outcome of the therapy exists. In
ddition we did not observe any correlation in the spec-
ficity of the B and T cell responses against HVR1 pep-
ides in HCV chronically infected patients. In fact in only
of 14 patients, whose PBMC proliferated to HVR1 pep-
ics of the Patient Population
C/nd)
Genotypec
1a 1b 2 2a 3 4 nd
1 2 2 6 1 1 11
1 10 1 1 4 0 3
0 1 1 0 1 0 2
0 3 0 0 1 0 0
sponders; R, responders; RR, responders with relapse. C corresponds
epatitis; CPH, chronic persistent hepatitis; nd, not determined.ABLE 1
cterist
logyb
/CAH-
/6/5/0
/0/3/2
/1/0
/0/0
, nonre
ctive hides, the simultaneous recognition of the same HVR1
TABLE 2
Anti-HVR1 Lymphoproliferative Responses in IFN-a Treated Patients
Patientsb No peptidec
HVR1 peptidesa
267 269 275 277 286 290 291 295
LTR
1 341 2.4 2.6 1.6 1.5 1.4 3.2 1.6 2.4
2 227 4 2.8 2.1 1.9 2.2 2.4 2.3 2.2
3 317 9.1 1.5 0.9 2.2 0.7 1 1 1.2
4 2143 0.7 1.2 0.3 0.6 0.6 1.3 0.7 0.6
5 320 0.7 7.8 1 0.6 1 2.5 0.8 1.5
6 158 2 1.8 1.3 1.4 2.3 1.8 1.6 1.4
7 600 3.1 3.8 1.5 1.3 8.1 1.5 0.6 4
8 230 4.4 1.2 2 1 4.2 1.7 1 0.8
9 2341 0.8 0.8 0.6 0.6 0.5 1.1 0.7 0.7
10 1200 0.8 0.1 0.9 0.8 0.7 1 0.8 0.8
11 1167 1.2 1.5 1.1 1.1 1 1.3 1 1.3
12 660 1.1 2.1 1 1.1 0.9 1.2 1 1
13 468 1.1 1.4 1 1.2 0.9 1.5 1.1 1.3
14 1700 1.3 0.6 0.6 0.6 0.6 1 0.8 0.6
15 2693 0.7 1.1 0.5 1 0.3 1.9 1.1 0.6
16 514 1.4 7.2 15 15 5.2 1.9 2.5 2.1
17 222 3.1 4.7 1.2 1.1 1.7 1.3 1.1 2.1
18 4000 1.1 3 0.4 1 1 2.5 1 0.7
19 1500 1.2 1 1.1 1.1 0.9 1 0.9 1
20 808 0.9 0.9 1 1 0.8 1.2 0.9 0.9
21 306 2.2 2.9 3.1 2.8 2.9 3.5 2.2 3.8
22 1500 0.5 9.1 0.3 1 1.9 7.6 1.2 5.3
23 2100 1 1.4 0.7 0.6 0.3 1.2 1 0.5
24 120 1 1 1 0.9 1 1 1 0.9
R
1 282 1.7 1.3 1.5 1 1.5 1.1 1.1 1.3
2 206 1.1 7 1 3.3 2.1 1.2 1.2 0.9
3 200 1.6 2.5 0.8 0.8 1 2.1 1.5 1
4 349 1.9 3.1 1.2 2 1.4 2.1 1.4 1.7
5 542 1.3 1.5 1.5 1.1 1.3 1.1 1 1.6
NR
1 400 1.8 1 0.9 0.7 1 1 2 1.8
2 1338 1.9 1.8 1.2 1 1.2 1.1 0.8 2.2
3 729 1.6 1.6 1.1 1.5 1.5 1.6 1.6 2
4 2820 0.5 0.8 0.7 0.6 0.5 1 1 0.5
5 1448 0.6 5.8 0.4 0.3 0.7 1.9 0.4 0.5
6 849 3.2 3.5 3 2.2 3.8 3.2 1.3 3.7
7 180 3.3 3.8 1.1 1.1 1.1 1.1 3.3 1.1
8 384 2.1 2.1 1.5 1.5 1.8 1.8 1 2
9 365 1.2 1.6 0.6 0.6 1 1 1.2 1.2
10 894 1.4 1.1 1 1 0.9 0.9 1 1
11 354 1.1 0.7 0.5 0.5 0.5 0.7 1 0.8
12 125 0.7 1.2 0.7 0.7 0.6 0.8 1 0.7
13 130 0.9 1 0.8 0.8 0.8 0.9 0.8 1.1
14 1598 1.7 1.8 0.8 0.8 1.1 1.9 0.7 1.3
15 464 1 2.7 1.3 1.3 0.9 1 1 1
16 623 0.4 0.7 1.2 1.2 0.3 0.5 0.3 0.6
17 790 0.7 2 0.6 0.6 0.8 2 1.3 0.6
18 227 1 2.1 0.7 0.7 1 1 1 1.1
19 1476 0.6 1 0.6 0.6 0.7 1 0.7 0.5
20 1319 1 0.8 0.8 0.8 1 0.9 1.2 1
RR
1 241 1 2 0.8 0.7 1 0.6 0.8 0.7
2 130 1.7 2.7 1.3 0.9 1.8 1.3 1.4 1.2
3 340 0.8 0.8 1 0.8 0.8 0.6 0.8 1.1
4 197 1 1.7 1 0.7 1 1.2 1 2
a Values are expressed as SI. Significant SI are in boldface type.
b LTR, long-term responder to IFN-a; R, responder to IFN-a; NR, nonresponder to IFN-a; RR, responder with relapse to IFN-a.
c Values express cpm.
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316 DEL PORTO ET AL.sequence by T cells and antibodies could be demon-
strated (Table 2 and Fig. 1).
HVR1 sequences elicit multispecific T cell responses
The analysis of the lymphoproliferative responses to
HVR1 demonstrated that PBMC from the majority of HCV-
infected patients recognized multiple HVR1 peptides. In
order to verify whether this was due to the activation of
polyclonal T cell responses or of cross-reactive T cells
we generated HVR1-specific T cell lines from two re-
sponsive patients. PBMC from one patient who showed
a long-term response to IFN-a treatment (n22, Table 2)
and from one nonresponder patient (n7, Table 2) were
expanded and kept in continuous culture by stimulation
with single HVR1 variants and IL-2. We obtained three T
cell lines specific for peptides 269, 267, and 291 from the
nonresponder patient and one T cell line specific for
variant 295 from the long-term responder patient. Block-
ing experiments using the anti-HLA-DR molecule mAb
L-243 demonstrated that all the cell lines were restricted
by DR molecules (data not shown). Subsequently, the
restriction of the HVR1-specific T cell lines was studied
using homozygous partially matched, lymphoblastoid
cell lines (LCL) as antigen-presenting cells (APC). As
shown in Fig. 2, while the T cell lines T2, T16, and T20
specific for variants 269, 291, and 267 proliferated in the
presence of DRB1*04041-LCL, the 295-responsive T11
ell line required DRB1*11011-LCL for correct presenta-
tion of the antigen. Experiments using as APC either
DRB1*0404- or DRB1*1101-expressing L cells confirmed
that the T cell lines T2 and T20 were restricted by the
T
Anti-HVR1 Lymphoproliferativ
No peptideb 267 269 27
1 133 1.8 1.1 1
2 119 1.1 1.1 1.5
3 186 0.8 1.7 1.2
4 215 1.4 2.2 1.8
5 145 1.1 1.2 1.2
6 228 1 1.3 1
7 260 1.1 1.9 1.1
8 231 1.3 1.3 1
9 203 0.8 0.9 1.2
10 505 1.3 1 0.9
11 222 1.8 1.3 1.4
12 187 1.4 1.9 1.2
13 356 2.1 1.9 1.3
14 530 1 0.6 0.9
15 418 1 0.8 1
a Values are expressed as SI.
b Values express cpm.HLA-DRB1*0404 molecule while the T11 T cell line was erestricted by HLA-DRB1*1101. In fact, proliferation values
of T2 and T20 T cell lines in response to antigen-pulsed
DRB1*04041-L cells were 15,565 6 1068 and 16,025 6
1213 counts per minute (cpm), respectively, while the
values of the same cells in the presence of unpulsed
APC were 1724 6 25 and 303 6 73 cpm. Similarly,
proliferation values of T11 cells with DRB1*11011-APC in
the presence or in the absence of the antigen were
17,195 6 3924 and 150 6 14 cpm, respectively. The
egree of cross-reactivity of T cell lines was evaluated by
esting their reactivity to a panel of HVR1 variants. As
hown in Fig. 3 while T cell lines T2 and T20 proliferated
n response to two and three other different HVR1 pep-
ides, respectively, the T cell lines T16 and T11 recog-
ized only the original peptides used for their selection.
To verify whether the differences in the cross-reactivity
f HVR1-specific T cells may be accounted for by focus-
ng the responses on different portions of the HVR1
equence, we mapped the T cell epitopes recognized by
2, T16, and T20 T cell lines in 269, 291, and 266 variants,
espectively. To identify the epitope(s) within the 27-aa-
ong HVR1 sequence responsible for T cell activation,
hree overlapping peptides covering the C-terminal, N-
erminal, and central sequences of variants 269 and 291
nd a subpeptide corresponding to the C-terminus of
VR1 variant 266 were synthesized and their stimulatory
ctivity was tested in a proliferation assay. As shown in
ig. 4, T cell lines T2, T16, and T20 always proliferated in
he presence of the C-terminal peptides, indicating that
LA-DR4 restricted T cell epitopes are located in the
VR1 sequences between aa 396 and 410. In the same
onses in Healthy Individuals
HVR1 peptidea
277 286 290 291 295
1.1 1.3 1.1 1.4 1.5
1.2 1.1 1.4 1.5 1.1
1 0.7 0.7 1 0.8
1.3 1.4 1.4 1.4 1.4
1.2 1.8 0.8 1.6 0.9
1.1 0.9 1.4 1 0.9
1.2 1.6 0.7 1 1
1.5 1 1.4 1.6 1.1
0.9 1.4 2 1 0.9
1.1 0.7 0.7 0.9 1.2
1.7 1.1 1.3 1.3 0.8
1.6 2.3 2.3 1.7 1.9
1.5 2.2 1.7 1.5 1.9
1.2 0.8 2.1 1.2 1
0.8 0.8 1.1 1 1ABLE 3
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317CROSS-REACTIVE T AND B RESPONSES TO HCV HVR1 AND IFN-apeptides corresponding to the N-terminal or central se-
quence of variant 269 (ATYTTGGSAAKTA, SAAKTAHR-
LASFF) was 3555 6 163 and 500 6 78 cpm, respectively,
hile proliferation of T cell line T16 with the N-terminal
nd central peptides of variant 291 (ETHSVGGSAAHTTS,
AAHTTSRFTSLF) was 1205 6 161 and 1325 6 9 cpm.
Interestingly we have recently mapped in the corre-
ponding region of variant 295 the T cell epitopes rec-
gnized by T cell clones derived from the T11 T cell line
Frasca et al., 1999) and we could confirm the same
pecificity for the T11 T cell line (data not shown). Thus
t seems that the carboxy-terminal region of HVR1 is
ndowed with helper T cell epitopes.
lonal HVR1-specific T cells are broadly cross-
eactive
We next investigated the HLA restriction of cross-
eactive HVR1 variants and their potency in stimulating T
ell lines T2 and T20. Restriction analysis using homozy-
FIG. 1. Reactivity of HVR1 peptides with sera of IFN-a treated patie
analyzed. The names of HVR1 peptides are indicated at the top of the
to a peptide of unrelated sequence was detected by ELISA. Average
Results are expressed as the difference between the average value
reactivities are shown as gray and black boxes. Gray boxes correspond
considered values statistically significant when they differed by more th
peptide.ous EBV transformed B cells (EBV-B) expressing theLA class II DRB1*0404 molecules (Fig. 5A) pulsed with
he original and the cross-reactive peptides demonstrate
hat both T2 and T20 T cell lines use the same restriction
lement to recognize both the original and the cross-
eactive peptides. To compare the potency of cross-
eactive variants, the proliferation of cell lines T2 and T20
n response to decreasing concentrations of HVR1 pep-
ides was assessed. The dose–response curve in Fig. 5B
hows that at the higher concentration (10 mg/ml) the
original and cross-reactive peptides induced similar pro-
liferative responses in both T cell lines, while a 10-fold
dilution of peptides 291 and 269 strongly decreased or
abolished proliferation of T cell lines T20 and T2, respec-
tively. A much weaker dose–response effect was ob-
served with all the other peptides. To definitively dem-
onstrate the cross-reactive nature of HVR1 T cell recog-
nition, clones from the line T20 were derived and their
ability to recognize multiple variants was tested. The
pattern of reactivity of representative clones (C6 and C7)
ra from 24 long-term responders (A) and 20 nonresponders (B) were
For each serum, binding of antibodies to the tested HVR1 peptide and
( A 405 nm) from two independent experiments have been determined.
tested HVR1 peptides and that of the unrelated controls. Significant
405 values #0.5, and black boxes correspond to OD405 values .0.5. We
ax (P , 0.003) from the background signal observed for the unrelatednts. Se
figure.
values
of the
to OD
an 3smto the original (267) and the cross-reactive (291, 266, 286)
G
t
v
M
o
s
s
c
(
1
r
b
e
a
w
t
s
g
d
p
l
3
f
r
p
e
l
M
d
p
r
q
t
u
P
n
midine
318 DEL PORTO ET AL.HVR1 peptide variants (Fig. 6A) and the dose–response
curve of C7 T cell clone (Fig. 6B) closely mirror those
observed with the parental cell lines. The confirmation of
wide cross-reactivity at the clonal level indicates that a
certain degree of TCR flexibility is present in the helper
anti-HVR1 T cell repertoire.
DISCUSSION
A high degree of sequence variation in the surface
proteins of infectious agents is thought to arise as a
consequence of immune selection of escape mutants.
Such mutation “hot spots” often contain or are part of
neutralizing epitopes (Weiner et al., 1992; Fox et al., 1989;
oudsmith et al., 1989; Javaherian et al., 1989). HVR1 of
he putative envelope protein E2 of HCV is the most
ariable part among all viral proteins (Weiner et al., 1991;
izushima et al., 1994) and represents another example
f this paradigm. In fact, anti-HVR1 antibodies have been
hown to prevent HCV infection both in vitro and in vivo,
uggesting that HVR1 is an important determinant for B
ells and for the induction of neutralizing antibodies
Farci et al., 1994, 1996; Zibert et al., 1995; Shimizu et al.,
996).
Recently it was shown that HVR1 is also a helper T cell
ecognition site. Activation of HVR1-specific T cells has
een demonstrated during HCV infection and the pres-
nce of such cells is associated with the production of
ntibodies against HVR1 (Shirai et al., 1999). In this study
FIG. 2. HLA restriction of HVR1-specific T cell lines. Proliferation of
(T11) was evaluated using as APC partially matched homozygous EBV-
bars) of 10 mg/ml of HVR1 peptides. Results are expressed as [3H]thye evaluated the immunogenicity of HVR1 in patientsreated with IFN-a and correlated the T and B cell re-
ponses with the course of the disease. Moreover by
enerating HVR1-specific T cell lines and clones we
emonstrate that truly broad cross-reactive T cells are
resent in the HVR1 T cell repertoire.
Using a panel of HVR1 synthetic peptides we detected
ymphoproliferative responses against HVR1 in about
0% of the PBMC isolated from patients chronically in-
ected with HCV. Previous studies on the helper T cell
esponse in chronic infection have indicated the core
rotein as one of the most immunogenic proteins (Ferrari
t al., 1994; Hoffmann et al., 1995; Lechmann et al., 1996).
Within this protein, immunodominant sequences corre-
sponding to aa 23–42, 66–85, and 131–150 have been
identified and the frequency of recognition by PBMC of
chronically infected patients was estimated at 10–20%
(Hoffmann et al., 1995). Our data indicate that a higher
evel of prevalence is displayed by epitopes in the HVR1.
oreover, since the peptides used for this analysis were
erived from a few, distantly related HVR1 variants, it is
ossible that by using a larger number of peptides rep-
esenting additional HCV variants an even higher fre-
uency of T cell reactivity would be observed. In line with
his hypothesis are results from a recent study in which,
sing only four HVR1 variants, it was demonstrated that
BMC from 20% of chronically infected patients recog-
ized HVR1 peptides (Shirai et al., 1999). Thus, it appears
that despite its large inter- and intraindividual sequence
ines specific for HVR1 variants 269 (T2), 291 (T16), 267 (T20), and 295
tologous EBV-B in the presence (black bars) or in the absence (white
incorporation.T cell l
B or auheterogeneity, HVR1 contains the most commonly recog-
si
t
c
319CROSS-REACTIVE T AND B RESPONSES TO HCV HVR1 AND IFN-anized T epitopes in chronically infected HCV patients
described to date. Our results showing that positive
responses to HVR1 peptides were significantly higher in
IFN-a long-term responder patients than in nonre-
ponder patients indicate that HVR1 may expand a CD41
FIG. 3. Proliferative response of specific T cell lines to different HVR
267 (T20) were incubated with autologous EBV-B in the presence of 1
ncorporation.
FIG. 4. Mapping of T cell epitopes within the HVR1 sequences. T ce
o peptides encompassing the C-terminus of peptide 269 (RLASFFTVG
ell lines pulsed with 10 mg/ml of peptide were used as APC. Results are exT cell population with a potential protective role against
HCV infection. A higher frequency of T cell responses to
E1, core, and NS4 proteins was also detected in sus-
tained responders to IFN-a therapy (Hoffmann et al.,
1995; Botarelli et al., 1993; Sarobe et al., 1996; Lasarte et
nts. T cell lines specific for variants 269 (T2), 291 (T16), 295 (T11), and
l of different HVR1 peptides. Results are expressed as [3H]thymidine
erative responses to HVR1 variants 269 (T2), 291 (T16), or 266 (T20) or
, 291 (RFTSLFSPGPQQN), or 266 (TSTLTSLFRPGASQK). Autologous B
31 varia
0 mg/mll prolif
PKQD)pressed as [ H]thymidine incorporation.
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320 DEL PORTO ET AL.al., 1998). Analysis of the T cell responses to core pep-
tides in these patients has recently demonstrated that
elimination of HCV is associated with the recognition of
multiple core epitopes, but also with a significantly
higher frequency of core-specific Th cell precursors (La-
sarte et al., 1998). Although our data strengthen the
mportance of CD41 T cells in the containment of HCV
infection we cannot exclude the possibility that the
weaker peripheral blood T cell responses to HVR1 in
nonresponders to IFN-a may be caused by persistent
sequestration of HCV-specific T cells within the liver of
patients with continuing disease.
The humoral immune response to HVR1 has been
previously investigated. Zibert et al. (1997; see also Lech-
ner et al., 1998) suggested that HVR1-specific antibodies
present in an early phase of infection are associated with
an acute self-limiting course of the disease. In chroni-
cally infected patients anti-HVR1 antibodies have been
detected and they seem to be directed mainly against
the C-terminus of HVR1 (Zibert et al., 1997b). A fraction of
these antibodies have been defined as isolate-indepen-
dent, because they cross-react with apparently unrelated
FIG. 5. Analysis of HVR1-specific T-cell cross-reactivity. (A) HLA r
DRB1*0404 were pulsed with 10 mg/ml of HVR1 variants and incubated
cell lines T2 and T20 to multiple HVR1 variants. T cell lines T2 and T20
ariants. Results are expressed as [3H]thymidine incorporation.HVR1 sequences and persist in sera of patients although wthe sequence of HVR1 changes rapidly (Scarselli et al.,
1995; Zibert et al., 1997b). In this study we confirm that
sera of almost all chronic patients were reactive with
HVR1 peptides and we demonstrate that the anti-HVR1
humoral response is independent of the clinical re-
sponse to IFN-a.
Our evidence that sera from the majority of chronically
infected patients were reactive to HVR1 peptides despite
the lack of HVR1-specific T cell responses is apparently
at variance with results by Shirai et al. (1999), who found
that the production of anti-HVR1 antibodies was strictly
dependent on the help provided by HVR1-specific T cells.
One possible explanation for this discrepancy is that
while Shirai et al. (1999) analyzed the reactivity of sera
gainst the HVR1 sequence of each patient’s own HCV
solate (i.e., isolate-specific antibodies), our analysis was
erformed with a panel of HVR1 peptides whose amino
cid sequences are likely to differ from those of the
atients’ infecting viruses, allowing for the detection of
ross-reactive, isolate-independent antibodies. Thus, we
annot exclude the possibility that differences in the
revalence of isolate-specific antibodies exist in patients
on of cross-reactive peptides. Homozygous EBV-B cells expressing
2 and T20 cell lines. (B) Dose–response proliferation of HVR1-specific
incubated with autologous EBV-B and different concentrations of HVR1estricti
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321CROSS-REACTIVE T AND B RESPONSES TO HCV HVR1 AND IFN-atherapy. This point deserves further investigation and
would provide helpful information on the mechanism
through which HVR1 cellular immune responses play a
protective role during HCV infection.
In this study we show that PBMC from the majority of
HCV chronically infected patients were reactive with mul-
tiple HVR1 peptides. The ability of some HVR1-specific T
cell lines and clones to proliferate in response to multi-
ple HVR1 variants indicates that this multireactivity is
also due to the activation of cross-reactive T cells. We
show that such cells were HLA-DR4 restricted and spe-
cific for an epitope located in the carboxy-terminus of the
HVR1 sequence (aa 396–410). Interestingly, in the same
region we have recently mapped T cell epitopes for
FIG. 6. HVR1-specific T cell clones proliferate to different HVR1
variants. (A) Proliferative responses of clones C6 and C7 to autologous
EBV-B pulsed with 10 mg/ml of HVR1 peptide variants. Results are
expressed as [3H]thymidine incorporation. (B) Dose–response prolifer-
tion of clone C7 to multiple HVR1 peptide variants. Clone C7 was
ncubated with autologous EBV-B and different concentrations of HVR1
eptide variants. Results are expressed as [3H]thymidine incorporation.HVR1-specific HLA-DR11 restricted T cell clones andidentified HVR1 variants acting as T cell receptor antag-
onists (Frasca et al., 1999). We suggested that the car-
boxy-terminal sequence of HVR1 variants presents a
pattern of conserved amino acid residues in which the
hydrophobic amino acid at position 399 could represent
a primary anchor for peptide binding to multiple DR
alleles (Frasca et al., 1999). Our finding that introducing a
nonconservative substitution (L to E) at residue 399 com-
pletely abolished stimulatory activity by variant 266 (data
not shown) gives further support to this hypothesis.
These data together with the identification of DR4 re-
stricted T cell epitopes in the C-terminal sequence of
HVR1 by Shirai et al. (1999) represent further evidence of
the immunodominance of this portion of the HVR1. More-
over the capability of multiple HVR1 sequences to stim-
ulate HLA-DR4 restricted T cell lines demonstrates that
the maintenance of MHC binding capacity is a property
shared by many HVR1 sequences. The finding that
HVR1-specific T cells can recognize peptides that carry
multiple amino acid substitutions is consistent with pre-
vious studies on the cross-reactivity of structurally re-
lated and unrelated antigens with the same TCR (Old-
stone, 1987; Hagerty and Allen, 1995; Evavold et al., 1995;
Bertoletti et al., 1998). However, the evidence that T cell
ines recognizing the same peptide–MHC complex (267
eptide–DR4 for T2 and T20 T cell lines; 291 peptide–
R4 for T20 and T16 T cell lines) display different pat-
erns of cross-reactivity may be explained by the exis-
ence of a unique spectrum of secondary T cell contacts
ecessary for the activation of each individual TCR
Evavold et al., 1992, 1995). In conclusion, our data con-
irm the high level of immunogenicity of HVR1 and sug-
est that this region can favor the amplification and the
aintenance of protective T cells during HCV infection.
hese data make the study of HVR1 extremely useful for
nderstanding the influence of viral variation on the evo-
ution of protective immunity during HCV infection. Finally
he cross-reactive nature of HVR1 recognition could rep-
esent a rationale for the development of synthetic HVR1
equences able to activate highly multispecific T cells.
MATERIALS AND METHODS
haracterization of patients
Table 1 shows the demographic, clinical, and virolog-
cal characteristics of the 53 patients enrolled in this
tudy. Diagnosis of HCV infection was based on stan-
ard clinical parameters and serological assays with the
econd-generation (c200/c22-3) Ortho HCV ELISA test
ystem (Ortho Diagnostics). In 51 of the 53 patients with
hronic HCV infection, liver biopsies were performed.
orty-two had chronic active hepatitis, 8 had chronic
ersistent hepatitis, and 3 had cirrhosis. The histological
tatus was defined according to conventional classifica-
ion.
Patients received between 3 and 6 mU of IFN-a on a
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322 DEL PORTO ET AL.3-week basis for periods ranging from 3 to more than 12
months. Among these patients, 24 were considered LTR
since they had normal ALT activity for a period over 6
months after the end of IFN-a treatment. The remaining
atients included 5 R (normalization of ALT activity, hav-
ng finished the IFN-a treatment within 6 months), 4 RR
normalization of ALT activity only during IFN-a treat-
ment), and 20 NR (patients who failed to normalize ALT
during IFN-a treatment). All blood samples analyzed
were drawn following IFN-a treatment. For all patients,
except the 5 responders, 20 ml of heparinized blood was
taken after at least 6 months from the end of IFN-a
therapy. As control the lymphocyte stimulating activity of
HVR1 peptides was analyzed in 15 healthy subjects that
showed no sign of past or present HCV infection (i.e.,
they were negative for anti-HCV in second-generation
ELISA tests).
HCV genotypes were determined by reverse transcrip-
tion-nested polymerase chain reaction (PCR) with sets of
primers derived from the highly conserved 59-noncoding
region of the HCV genome and classified according to
Simmonds et al. (1993).
Choice of a representative panel of HVR1 peptides
reproducing the HVR1 sequence of natural isolates
Synthetic peptides reproducing natural HVR1 variants
that approximately cover the observed sequence vari-
ability were generated as described by Puntoriero et al.
(1998) and synthesized as multiple antigenic peptides
(Pessi et al., 1990).
Accession numbers and sequences are as follows:
264, GenBank D12967, QTRTVGGQMGHGVRGLTSLF-
SAGSARN, bp 46–126; 266, GenBank D00574, HTRVTG-
GVQGHVTSTLTSLFRPGASQK, bp 1240–1320; 267, Gen-
Bank L19383, ETHTSGGSVARAAFGLTSIFSPGAKQN, bp
46–126; 269, GenBank U24616, ATYTTGGSAAKTAHR-
LASFFTVGPKQD, bp 22–102; 275, PIR PQ0835, STRIT-
GGSMARDVYRFTGFFARGPSQN, aa 6–32; 277, GenBank
D10934, NTYVTGGAAARGASGITSLFSRGPSQK, bp 1491–
1571; 284, GenBank X79672, NTRVTGGVQSRTTGT-
FVGLFTPGPSQR, bp 1–81; 286, GenBank D12952,
STRVSGGQQGRAAHSLTSLFTLGASQN, bp 46–126; 288,
GenBank M84754, STIVSGGTVARTTHSLASLFTQGASQK,
bp 1491–1571; 290, GenBank S24080, NTYVTGGSA-
GRAVAGFAGLLQPGAKQN, bp 46–126; 291, GenBank
S35631, ETHSVGGSAAHTTSRFTSLFSPGPQQN, bp 580–
660; 295, GenBank D10687, NTHTVGGTEGFATQRLTSL-
FALGPSQK, bp 1180–1260; 296, GenBank D43651, NTH-
VTGGVVARNAYRITTFLNPGPAQN, bp 39–119.
ELISA with MAPs
ELISA multiwell plates (Immunoplate Maxisorp; Nunc,
Roskilde, Denmark) were coated overnight at 4°C with 1
mg/ml of MAPs in 50 mM NaHCO3 pH 9.6. The plates
were washed in PBS/Tween (PBS/0.05% Tween 20) andblocked for 1 h at 37°C in 250 ml/well of ELISA blocking
uffer (5% nonfat dry milk, PBS/0.05% Tween 20). Human
CV plasma, diluted 1:50, was incubated for 2 h at room
emperature in 100 ml of ELISA blocking buffer containing
2.5 mg/ml of unrelated MAPs. One hundred microliters of
preincubated plasma mixture was added to each well
and incubated overnight at 4°C. Plates were then
washed with PBS/Tween and incubated for 4 h at 4°C in
100 ml/well of goat anti-human IgG (Fc-specific) alkaline
hosphatase-conjugated Abs (Sigma Chemical Co., St.
ouis, MO; diluted 1:5000 in ELISA blocking buffer). Al-
aline phosphatase was revealed by incubation with 100
ml/well of a 1 mg/ml solution of p-nitrophenyl phosphate
in substrate buffer (10% diethanolamine buffer, 0.5 mM
MgCl2, adjusted to pH 9.8 with HCl). Results were re-
orded as differences between OD405 nm and OD620 nm by
an automated ELISA reader (Labsystems Multiskan
Bichromatic, Helsinki, Finland).
Generation of T cell lines, T cell clones, and EBV-B
The T cell lines were generated by stimulating patient
PBMC with 10 mg/ml synthetic peptide for 10 days. Acti-
ated T cells were maintained in culture with irradiated
utologous PBMC, peptide, and 20 U/ml of human recom-
inant IL-2 (Boerhinger Mannheim, Mannheim, FRG) and
sed at least 3 weeks after the first stimulation. HVR1-
pecific T cell lines were cloned by limiting dilution in
erasaky plates (0.3 cells/well) in the presence of allogenic
BMC, 0.5 mg/ml phytohemagglutinin (Murex, England),
nd 20 U/ml human recombinant IL-2. The peptide speci-
icity of T cell lines and clones was assessed by using a
roliferation assay. Homozygous lymphoblastoid cell lines
sed as APC were PE117 (DRA*0101, DRB1*0404,
RB4*0101, DQA1*03, DQB1*0302, DPA1*01, and
PB1*0401), MGAR (DRA*0102, DRB1*1501, DRB5*0101,
QA1*0102, DQB1*0602, DPA1*01, and DPB1*0401),
Z070782 (DRA*0101, DRB1*0102, DRB6*0101, DQA1*01,
QB1*0501, DPA1*01, and DPB1*0401), and Sweig
DRB1*1101, DQA1*0501, and DQB1*0301).
EBV transformed B cells from patients were generated
y incubation of 5 3 106 PBMC with EBV obtained from
the Marmoset lymphoblastoid cell line B95-8 as previ-
ously described (Del Porto et al., 1994).
DRB1*0404 and DRB1*1101 transfectants were gener-
ated by cotransfection of DRA and DRB cDNAs in the
DAP.3 subline of murine L cells and they were kindly
provided by Dr. G. Lombardi (Hammersmith Hospital,
London, UK).
Proliferation assays
PBMC (1 3 105), isolated from freshly heparinized
blood, were resuspended in 0.2 ml of RPMI 1640 (Gibco)
containing 10% human serum and incubated at 37°C
with 5% CO2 with 10 mg/ml of synthetic peptide.
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before the cells were harvested.
Stimulation indices (SI) were calculated as the ratio of
[3H]thymidine incorporation in the presence of antigen in
elation to the control. SI $ 3 were considered to indicate
ositive proliferative responses. Standard deviations of
he mean counts per min of triplicate cultures were
onsistently below 30%.
The proliferative response of T cell lines and clones
as assessed by incubation of 20 3 103 T cells either
with 40 3 103 mitomycin-C treated autologous B cell
lines or with 30 3 103 mitomycin-C treated L cell trans-
fectants pulsed with synthetic peptides. After 2 days, the
cells were pulsed with 1 mCi of [3H]thymidine and incu-
bated for 18 h before the cells were harvested. The
results are expressed as the mean counts per min of
triplicate determinations. Data are representative of at
least three independent experiments.
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